Current Research Studies
MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED (12-17 YEARS) INCLUDING A SINGLE OPEN-LABEL ARM (6-11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO)
CIMCare
What is the goal of the study?
This Phase 3, multicenter study to evaluate the efficacy, safety, and PK of CZP in pediatric study participants will include 2 cohorts: Cohort A, enrolling study participants aged 12 to 17 years (inclusive), and Cohort B, enrolling study participants aged 6 to 11 years (inclusive). For Cohort A, this study will be randomized, parallel-group, double-blind, and placebo-controlled through Week 16 with one CZP arm; all study participants will receive CZP from Week 16 to Week 52 and through the subsequent 104-week OLE Period. For Cohort B, the study has a single open-label active treatment arm from Week 0 to Week 52 followed by a 104-week OLE.
Who can participate in the study?
Please contact the study team listed below to learn more.